References
- Cooper RG, Magwere T. Chloroquine: novel uses & manifestations. Indian J Med Res 2008; 127:305–316.
- Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20:160–174.
- Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and review of the literature. Clin Ther 2008; 30:930–940.
- Millard TP, Smith HR, Black MM, Barker NW. Bullous pemphigoid developing during systemic therapy with chloroquine. Clin Exp Dermatol 1999; 24:263–265.
- Millard TP, Ratnavel R. Cutaneous hyperpigmentation during therapy with hydroxychloroquine. Clin Exp Dermatol 2004; 29:91–99.
- Geraminejad P, Stone MS, Sontheimer RD. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus. Lupus 2004; 13:473–477.
- Di Giacomo TB, Valente NYS, Nico MMS. Chloroquine-induced hair depigmentation. Lupus 2009; 18:264–266.
- Marriot P, Borrie PF. Pigmentary changes following chloroquine. Proc Med Soc Med 1975; 68:25–26.
- Rood MJ, Vermeer MH, Huizinga TWJ. Hyperpigmentation of the skin due to hydroxychloroquine. Scand J Rheumatol 2008; 37:158–160.
- Reynaert S, Setterfield J, Black MM, Hydroxychloroquine induced pigmentation in two patients with systemic lupus erythematosus. J Eur Acad Dermatol Venereol 2006; 20:487–488.
- Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138:1231–1233.